Novartis-partnered biotech nabs new cash, boosting efforts to develop 'functional cure' for chronic hepatitis B
Every year, 820,000 people die of chronic hepatitis B infections globally, and 1.5 million get infected, despite the availability of vaccines and treatments, according to the CDC. Current standard-of-care treatments can be effective in stopping virus replication, but they require patients to be on meds for life.
Bluejay Therapeutics, which was founded in 2019, is trying to change that, aiming to develop a functional cure for hepatitis B infections by making HBsAg — viral protein-surface antigens — completely undetectable within six months of treatment. And it’s got a new round of cash to try making it a reality.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.